With this much community interest and this much preclinical data, what is actually blocking a proper human RCT? Patent economics? Regulatory category? Discussing the structural reasons.
The BPC-157 human-evidence gap: why has nobody run the trial?
Replies
No replies yet. Be the first to add one.
Mostly economics: an unpatentable decades-old sequence has no sponsor with exclusivity to recoup trial costs. The compounding-category status adds friction. Classic orphaned-compound problem.
There have been small registered studies announced over the years that quietly disappeared. An academic consortium is realistically the only path.